Impacto de la resistencia microbiana en las decisiones terapéuticas de las infecciones de transmisión sexual

[1]  J. G. Kusters,et al.  Mycoplasma genitalium in Spain: prevalence of genital infection and frequency of resistance to macrolides. , 2017, Enfermedades infecciosas y microbiologia clinica.

[2]  X. Vallès,et al.  Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients infected with gonorrhea. , 2017, Enfermedades infecciosas y microbiologia clinica.

[3]  Janine Paynter,et al.  Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study , 2017, The Lancet.

[4]  Suzanna C Francis,et al.  Sexually transmitted infections: challenges ahead. , 2017, The Lancet. Infectious diseases.

[5]  J. Jensen,et al.  Mycoplasma genitalium Macrolide and Fluoroquinolone Resistance: Prevalence and Risk Factors Among a 2013–2014 Cohort of Patients in Barcelona, Spain , 2017, Sexually transmitted diseases.

[6]  C. Fairley,et al.  Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study , 2016, Sexually Transmitted Infections.

[7]  M. Cusini,et al.  2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.

[8]  N. O’Farrell.  Control of gonorrhoea and chlamydia in the UK , 2016, The Lancet.

[9]  W. I. van der Meijden,et al.  2016 European guideline on the management of non-gonococcal urethritis , 2016, International journal of STD & AIDS.

[10]  J. Hocking,et al.  The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Horner.  Editorial Commentary: Mycoplasma genitalium and Declining Treatment Efficacy of Azithromycin 1 g: What Can We Do? , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Unemo,et al.  In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against Macrolide-Resistant and -Susceptible Mycoplasma genitalium Strains , 2014, Antimicrobial Agents and Chemotherapy.

[13]  D. Carnicer-Pont,et al.  First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. , 2012, Enfermedades infecciosas y microbiologia clinica.

[14]  M. Yasuda,et al.  Selection of Mycoplasma genitalium strains harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 g dose of azithromycin , 2011, Sexually Transmitted Infections.